ArticleBMC gastroenterology2026
Transjugular liver biopsy in patients with unexplained liver dysfunction and bleeding tendency: a safety and efficacy analysis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTransjugular liver biopsy (TJLB) enables histopathological diagnosis of liver disease and simultaneous assessment of the hepatic venous pressure gradient (HVPG).
aimsTo assess the diagnostic adequacy and safety of TJLB in combination with HVPG measurement in patients with unexplained Liver Dysfunction and hemorrhage tendency.
methodsSeventy-seven TJLB procedures were performed in 58 patients with unexplained liver dysfunction using the COOK Medical TJLB kit. Biopsy quality was assessed by specimen length, number of complete portal tracts, diagnostic yield, and procedure-related complications. Subgroup analyses were conducted according to HVPG levels.
resultsAll procedures yielded adequate histopathological samples. The mean specimen length was 8 mm (range, 5–13 mm), with a mean of 9 complete portal tracts (range, 4–20). TJLB identified the underlying etiology in 72.4% of patients, including 70.7% of those with ascites and 72.7% of those with coagulopathy. Among patients who underwent HVPG measurement, higher HVPG values were associated with shorter specimen length and fewer portal tracts. No procedure-related complications were observed.
conclusionsTJLB combined with HVPG measurement is a safe and effective approach for diagnosing liver disease in patients with unexplained liver dysfunction and bleeding tendency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.